FindTrial
Sign In

Lutetium [177Lu] oxodotreotide/dotatate

DRUG2 trials

Sponsors

Advanced Accelerator Applications, Sociedad Española de Medicina Nuclear e Imagen Molecular

Conditions

Digestive System DiseasesDigestive System NeoplasmsEndocrine Gland NeoplasmsEndocrine System DiseasesGastroenteropancreatic Neuroendocrine TumorsGastrointestinal DiseaseGastrointestinal NeoplasmsIntestinal Diseases

Phase 2

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Active, not recruitingNCT04711135
Advanced Accelerator ApplicationsGastroenteropancreatic Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma
Start: 2022-08-31End: 2034-02-06Updated: 2026-02-12

Unknown Phase

Spanish Series of Patients Treated With the Radionuclide Lutetium177
RecruitingNCT04949282
Sociedad Española de Medicina Nuclear e Imagen MolecularDigestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms +15
Start: 2021-05-10End: 2035-12-31Target: 5000Updated: 2022-12-23

Related Papers

Safety and dosimetry of [<sup>177</sup>Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study.
2025-04-083 citations
Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
European Journal of Nuclear Medicine and Molecular Imaging2023-03-0650 citations